Lovastatin
FDA-approved product (tablet, oral), marketed as Altoprev, Lovastatin, Mevacor.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Atherosclerosis
- Cardiovascular disease
- Coronary artery disease
- Coronary atherosclerosis
- Hypercholesterolemia
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Hmg coa reductase inhibitors
- FDA pharmacologic class
- HMG-CoA Reductase Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA56.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli34.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae27.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis38.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Lovastatin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC
NCT00313859 · start 2005-09
Registered record
- Registry ID
- NCT00313859
- Conditions
- Colorectal Cancer; Metastasis
- Interventions
- simvastatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2005-09
- Completion
- 2007-08
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionColorectal Cancer; MetastasisInterventionsimvastatinPhasePhase 2Registry statusCompletedBioequivalence Study of Simvastatin Tablets, 80 mg of Dr. Reddy's Under Fed Conditions
NCT01167933 · start 2005-01
Registered record
- Registry ID
- NCT01167933
- Conditions
- Healthy
- Interventions
- Simvastatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2005-01
- Completion
- 2005-04
- Enrolment
- 44
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionSimvastatinPhasePhase 1Registry statusCompletedEffects on NF-κB Activity: High Dose Simvastatin Versus Combination Therapy With Ezetimibe
NCT01424891 · start 2004-04
Registered record
- Registry ID
- NCT01424891
- Conditions
- Type 2 Diabetes; Inflammation
- Interventions
- Simvastatin 80 mg; Sim10/Eze10; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2004-04
- Completion
- 2011-08
- Enrolment
- 31
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionType 2 Diabetes; InflammationInterventionSimvastatin 80 mg; Sim10/Eze10; PlaceboPhaseNot applicableRegistry statusCompletedEffects of Statin Medications on Mental Processes, Behavior, and Serotonin Levels
NCT00330980 · start 2000-04
Registered record
- Registry ID
- NCT00330980
- Conditions
- Dyslipidemias
- Interventions
- 40 mg Pravastatin (Pravachol); 20 mg Simvastatin; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2000-04
- Completion
- 2004-03
- Enrolment
- 1,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDyslipidemiasIntervention40 mg Pravastatin (Pravachol); 20 mg Simvastatin; PlaceboPhasePhase 4Registry statusCompletedDrugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes
NCT00004266 · start 1993-08
Registered record
- Registry ID
- NCT00004266
- Conditions
- Diabetic Nephropathy
- Interventions
- Lisinopril; Nifedipine; Simvastatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1993-08
- Completion
- 1999-07
- Enrolment
- 160
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDiabetic NephropathyInterventionLisinopril; Nifedipine; SimvastatinPhasePhase 3Registry statusCompleted